Health officials are on the verge of approving a first-of-its-kind treatment for tens of thousands of Americans suffering from a debilitating blood disorder. Last month, a Food and Drug Administration () advisory committee announced it would consider approving the gene-editing drug Casgevy to treat sickle cell disease, a lifelong, excruciatingly painful disorder that deforms blood cells. The drug was recently to treat sickle cell and transfusion-dependent β-thalassemia - a shortage of red blood cells that leads to severe anemia. It's expected to cost the approximately £1million ($1.25 million) per patient.
Load More
Load More